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Atrial fibrillation (AF) is the most common cardiac arrhythmia. Developing effective
and safe anti-AF drugs remains an unmet challenge. Simultaneous block of both
atrial-specific ultra-rapid delayed rectifier potassium (K+) current (IKur) and the Na
+
current (INa) has been hypothesized to be anti-AF, without inducing significant QT
prolongation and ventricular side effects. However, the antiarrhythmic advantage of
simultaneously blocking these two channels vs. individual block in the setting of
AF-induced electrical remodeling remains to be documented. Furthermore, many IKur
blockers such as acacetin and AVE0118, partially inhibit other K+ currents in the
atria. Whether this multi-K+-block produces greater anti-AF effects compared with
selective IKur-block has not been fully understood. The aim of this study was to
use computer models to (i) assess the impact of multi-K+-block as exhibited by
many IKur blokers, and (ii) evaluate the antiarrhythmic effect of blocking IKur and
INa, either alone or in combination, on atrial and ventricular electrical excitation
and recovery in the setting of AF-induced electrical-remodeling. Contemporary
mathematical models of human atrial and ventricular cells were modified to incorporate
dose-dependent actions of acacetin (a multichannel blocker primarily inhibiting IKur
while less potently blocking Ito, IKr, and IKs). Rate- and atrial-selective inhibition
of INa was also incorporated into the models. These single myocyte models were
then incorporated into multicellular two-dimensional (2D) and three-dimensional (3D)
anatomical models of the human atria. As expected, application of IKur blocker
produced pronounced action potential duration (APD) prolongation in atrial myocytes.
Furthermore, combined multiple K+-channel block that mimicked the effects of
acacetin exhibited synergistic APD prolongations. Synergistically anti-AF effects following
inhibition of INa and combined IKur/K
+-channels were also observed. The attainable
maximal AF-selectivity of INa inhibition was greatly augmented by blocking IKur or
multiple K+-currents in the atrial myocytes. This enhanced anti-arrhythmic effects
of combined block of Na+- and K+-channels were also seen in 2D and 3D
simulations; specially, there was an enhanced efficacy in terminating re-entrant excitation
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waves, exerting improved antiarrhythmic effects in the human atria as compared to a
single-channel block. However, in the human ventricular myocytes and tissue, cellular
repolarization and computed QT intervals were modestly affected in the presence of
actions of acacetin and INa blockers (either alone or in combination). In conclusion, this
study demonstrates synergistic antiarrhythmic benefits of combined block of IKur and
INa, as well as those of INa and combined multi K
+-current block of acacetin, without
significant alterations of ventricular repolarization and QT intervals. This approach may
be a valuable strategy for the treatment of AF.
Keywords: atrial-selective block, atrial fibrillation, sodium and potassium current block, multiscale simulation,
synergistic antiarrhythmic effect
INTRODUCTION
Despite recent advances in the management of Atrial fibrillation
(AF), the world’s most common cardiac arrhythmia (Dobrev
et al., 2012; Nattel and Dobrev, 2017), developing effective
and safe antiarrhythmic drugs for treatment of AF remains
challenging (Aguilar-Shardonofsky et al., 2012; Aguilar et al.,
2015). Frequently these antiarrhythmic agents promote
ventricular arrhythmias (Dobrev et al., 2012; Woods and
Olgin, 2014; Voigt and Dobrev, 2016) by prolonging cellular
action potential durations (APDs). The associated QT-interval
prolongation can lead to life-threatening consequences.
Developing atrial-selective drugs is acknowledged to be a current
strategy for the treatment of AF (Burashnikov et al., 2007).
Atrial and ventricular tissues show intrinsic regional
differences in their cellular ion channel properties, thus
suggesting a basis for developing atrial-selective drugs. For
example, the atrial and ventricular fast sodium (Na+) channel
currents (INa) exhibit different voltage-dependent inactivation
properties, opening the opportunity for atrial-selective Na+
channel blockade (Burashnikov et al., 2007; Antzelevitch and
Burashnikov, 2009; Zygmunt et al., 2011). Previous simulation
studies have demonstrated that by optimizing state-dependent
Na+-channel blocking dynamics (i.e., drug-channel interaction
parameters), atrial-selective block of INa could be achieved
and that could maximize pharmaceutical effects on the atria
while minimizing their proarrhythmic actions in the ventricles
(Aguilar-Shardonofsky et al., 2012; Aguilar et al., 2015).
Another tissue-specific difference between the atria and
ventricles is that the ultra-rapid delayed rectifier potassium
current (IKur, carried by the KV1.5 channel) contributes to
repolarization in the atria but plays little role in the ventricles
(Tamargo et al., 2009; Ravens andWettwer, 2011). Recent studies
suggest that atrial-selective blockade of IKur may be an effective
pharmacological treatment of AF (Li et al., 2008; Pavri et al.,
2012; Loose et al., 2014; Ford et al., 2016). Although the efficacy
of IKur block in the treatment of AF remains controversial
(Burashnikov and Antzelevitch, 2008), multiple IKur blockers
have been developed (Tamargo et al., 2009; Loose et al., 2014;
Wettwer and Terlau, 2014; Ford et al., 2016). Interestingly, these
IKur blockers actually target multiple channels, and are known
to inhibit other K+ currents including Ito and IK,ACh in the atria
(Burashnikov and Antzelevitch, 2008). Examples of such blockers
include AVE0118 (Gögelein et al., 2004), AVE1231 (Wirth et al.,
2007), AZD7009 (Persson et al., 2005), and acacetin (Li et al.,
2008). Among these channel blockers, acacetin, a natural flavone
initially isolated from a traditional ChinesemedicineXuelianhua,
potently blocks IKur, Ito, and IK,ACh, and has a smaller potency
in inhibiting IKr and IKs (Li et al., 2008), similar to AVE0118
(Gögelein et al., 2004; Haan et al., 2006). Acacetin is regarded
as a promising atrial-selective agent for the treatment of AF
(Li et al., 2008). However, the actions of acacetin on atrial
electrophysiology, especially its effects following AF-induced
electrical remodeling of atrial electrophysiological properties
(Dobrev et al., 2012), remain to be elucidated. Furthermore,
since most IKur blockers inhibit other K
+ channels, the question
whether the “additional” inhibitive actions produce favorable
antiarrhythmic effects has not been addressed thoroughly. A
better understanding of these effects of modulating multiple ion
channels on atrial excitation and recovery/repolarization may
provide insights into evaluating and developing antiarrhythmic
drugs.
Interestingly, simultaneous multiple-channel blocking of both
depolarization and repolarization currents is attracting more
attention since empirical observations suggest that such multi-
channel blockers generallymediatemore effective antiarrhythmic
effects (Kirchhoff et al., 2015; Reiffel et al., 2015; Hartmann
et al., 2016). A recent numerical and experimental study on the
canine heart (Aguilar et al., 2015) suggested that blocking K+
currents enhanced the anti-arrhythmic effects and AF-selectivity
of INa blockade. In their study, IKur block was modeled using a
simple pore block scheme by reducing the conductance of the
channel. As the kinetics of drug action plays an important role
in the effects of IKur blockers (Scholz et al., 2013; Ellinwood
et al., 2017), in simulating IKur block a state-dependent block
model reproducing a realistic blocker is more favorable. Once
again, the effects of combined INa and IKur block on the human
atria, especially in the setting of AF-induced electrical remodeling
which reduced IKur, remain to be elucidated. It is also unclear
how multiple-channel blockade may affect QT interval.
In the present study, it was hypothesized that combined block
of INa and K
+-currents (predominantly IKur) could produce
antiarrhythmic benefits compared with the application of either
blocker alone in the setting of AF-induced electrical remodeling.
We have tested the hypothesis with the following three aims:
(i) to identify and illustrate the effects of the realistic IKur
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blocker, acacetin, on atrial electrophysiology following AF-
related remodeling; (ii) to assess whether combined INa and
IKur block produce synergistic antiarrhythmic effects; and (iii) to
investigate the action of such drug combinations on ventricular
electrophysiology.
METHODS
Modeling Electrophysiology of the Human
Heart
To simulate human atrial electrophysiology, an updated Colman
et al. model for atrial electrophysiology (Colman et al., 2013,
2017) was used. For in silico study of effects of chronic AF-
(cAF) induced electrophysiological remodeling on the atria, we
incorporated the cAF model parameters from our previous study
(Colman et al., 2013) into the updated atrial single cell model (for
details please see Online Supplement Material 1.1).
To assess the effects of the anti-AF drugs on the human
ventricles, simulations were performed to investigate the actions
of the anti-AF drugs on the ventricular AP, INa and QT intervals
in the electrograms. In these simulations, the mathematical
model developed byO’Hara et al. (2011) was used to represent the
ventricular electrophysiology. Additionally, the INa formulation
in the model was replaced by the one in the Luo–Rudy model
(Luo and Rudy, 1994), which enabled electrical excitation to
propagate in the tissue model.
More detailed descriptions of the electrophysiological models
of human atrial and ventricular cells are given in Online
Supplementary Material 1.1.
Modeling State-Dependent INa Block
As in previous studies (Aguilar-Shardonofsky et al., 2012; Aguilar
et al., 2015), INa block was simulated using a guarded receptor
model with dynamical drug-channel interactions. This approach
allows for investigations of the role of the specified parameters
for selected INa blockers, and effects of combined IKur block
on the atrial selectivity of Na+-channel block. The guarded
receptor model considers the binding and unbinding kinetics
of the drug to INa channels in a drug concentration-dependent
manner. They can be described by first-order transition equations
(Aguilar-Shardonofsky et al., 2012; Aguilar et al., 2015). It was
also assumed that the drug predominantly binds to the activated
and/or inactivated states of INa. The blockade of INa is given by
Aguilar-Shardonofsky et al. (2012) and Aguilar et al. (2015):
INa = gNa (1− BA − BI)m
3hj (Vm − ENa) (1)
dBA
dt
= KA [DNa+ ]m
3hj (1− BA − BI)− LABA (2)
dBI
dt
= KI [DNa+ ] (1− h) (1− BA − BI)− LIBI (3)
where gNa is the maximum conductance of INa; BA and BI are
the fractional blockade of activation and inactivation channels;m
is the activation gate state variable, h and j are the inactivation
gate state variables; Vm the transmembrane potential; ENa the
reversal potential of Na+; KA, KI the binding constants and LA,
LI the unbinding constants; [DNa+ ] is the concentration of a
Na+-blocker. As in previous studies (Aguilar-Shardonofsky et al.,
2012; Aguilar et al., 2015), a concentration of 60µMwas utilized
unless otherwise stated; this concentration was chosen based on
previous experimental and modeling studies (Zhu et al., 2006;
Moreno et al., 2011; Aguilar-Shardonofsky et al., 2012; Aguilar
et al., 2015); a parameter set (KA = 100 ms
−1
· M−1, KI = 100
ms−1· M−1, LA = 1 ms
−1, LI = 0.01 ms
−1) was first used to
represent the kinetics of an INa-selective blocker.
In our investigations of the AF-selectivity of INa block
following AF-remodeling, the binding and unbinding constants
of the INa blockers were varied to evaluate the dependence of INa
block on these parameters, and whether an atrial-selective anti-
AF action could be achieved in cAF-remodeled myoctes. The AF-
selectivity of Na+-channel blockade was defined as the product
of atrial-selectivity, rate-selectivity and block efficacy. With
fractional block (Bf) by Na
+-channel blockers being measured as
the relative reduction in the peak of INa, the rate-selectivity was
defined as the ratio of Bf measured in an atrial myocyte paced
at 6Hz to that paced at 1Hz (Aguilar-Shardonofsky et al., 2012;
Aguilar et al., 2015). Atrial-selectivity was used to determine the
extent of atrial-ventricular difference in response to each drug.
This was represented by the ratio of Bf observed from an atrial
myocyte to that of a ventricular cell both paced at 1Hz. In this
study, we defined block efficacy (E) as:
E =
1.0
1.0+
(
0.5
Bf,6Hz
)4 (4)
where Bf,6Hz is the fractional block of INa measured in an
atrial cell paced at 6Hz. Different from Aguilar et al. (2015),
we introduced block efficacy to constrain the measure of AF-
selectivity when the fractional block observed in a ventricular
cell paced was minimal (and could result in a great atrial-
selectivity), which otherwise could give a great value in AF-
selectivity regardless of a small Bf,6Hz.
To assess the dependence of the AF-selectivity of INa block on
the drug action kinetics, the unbinding constants LA and LI were
first varied over a parameter space from 10−5 to 100 ms−1, while
KA and KI were fixed (see Figure S6 of online Supplementary
Materials for more details). The resultant unbinding constants
were used in subsequent optimizations varying KA and KI . The
parameter space was {1, 10, 100, 500, 2,500, 10,000} for KA and
{1, 10, 100, 200, 500, 2,500} for KI . The parameter space fell
into a likely range of INa blockers as summarized in Aguilar-
Shardonofsky et al. (2012).
Modeling Effects of Acacetin on Atrial and
Ventricular Electrophysiology
Acacetin was the chosen IKur blocker in the present study. To
reveal the functional effects of (i) pure IKur block vs. (ii) the
effects of combined K+ currents block by acacetin on human
atrial electrophysiology, the actions of acacetin were modeled
by considering its effects on (a) IKur only, and (b) all the
respective K+ currents as detailed in Table 1. This approach
allows for modeling the effects of the selective IKur block as well as
uncovering the role of “additional” inhibitory effects of acacetin
on other K+ currents.
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TABLE 1 | Concentration-dependent block of K+-currents by acacetin (Li et al.,
2008; Wu et al., 2011).
IKur Ito IKr IKs
IC50 (µM) 3–3.2 9.3 32.4 81.4
Hill coefficient 0.8 0.9 0.9 0.8
Fractional inhibition at 3.2µM 50% 28% 11% 7%
Modeling Effect of Acacetin on IKur
Previous modeling studies have demonstrated the important role
of the kinetic properties of drug actions in IKur block (Tsujimae
et al., 2008; Almquist et al., 2010; Scholz et al., 2013). In addition,
the pharmaceutical effects of acacetin on IKur are characterized
by use- and rate-dependencies (Wu et al., 2011), which have
also been observed in other IKur blockers (Pavri et al., 2012;
Ford et al., 2016). Therefore, it was necessary to adopt a state-
dependent block model (Brennan et al., 2009) for simulating
the blockade of IKur by acacetin. Similar to our approach for
modeling INa block, the binding and unbinding kinetics of a drug
was described by a first-order transition equation, in contrast
to simulating IKur block by reducing its conductance in Aguilar
et al. (2015). Experimental studies revealed that acacetin binds
to both the open and closed gates of KV1.5 (Wu et al., 2011).
Therefore, following the guarded receptor formulas given in
Equations (1–3), the formulation of inactivation-state binding
and unbinding kinetics in INa block was modified to simulate
the closed-state block of IKur by acacetin. The guarded receptor
model of IKur block by acacetin is given by:
IKur = gKur (1− BO − BC) ai (Vm − EK) (5)
dBO
dt
= KO exp
(
ZKO
VmF
RT
)
[DK+ ] ai (1− BO − Bc)
−LO exp
(
−ZLO
VmF
RT
)
BO (6)
dBc
dt
= Kc exp
(
ZKc
VmF
RT
)
[DK+ ] (1− a) i (1− BO − Bc)
−Lc exp
(
−ZLc
VmF
RT
)
Bc (7)
where gKur is the conductance of IKur; Bo and BC are the fractional
block on open and closed state variables, respectively; a and
i are the activation and inactivation gate variables; EK is the
reversal potential of potassium; F, R, and T are the Faraday’s
constant, universal gas constant and temperature respectively.KO
and Kc are the binding constants; LO and Lc are the unbinding
constants; ZKO, ZLO,ZKc and ZLc are the drug charge parameters
for the corresponding binding or unbinding processes; [DK+ ]
is the concentration of acacetin applied. The binding and
unbinding parameters were obtained by fitting the model to the
experimental data on the rate-dependent blockade of IKur by
acacetin (Wu et al., 2011), as detailed in Online Supplementary
Material 1.1.
Figure 1 shows a simulated frequency-dependent block of
IKur by acacetin, and this is compared to the experimental
data (Figures 1A,B). As shown, repeating the voltage command
(Figure 1B, insert) at 0.5Hz resulted in an approximately 50%
blockade in this current after application of 3µM acacetin.
Increasing the voltage command rate to 4Hz significantly
increased the relative fractional block to approximately 63%
(Figure 1C).
Modeling Effect of Acacetin on Ito, IKr, and IKs
In addition to inhibiting IKur in the atria, acacetin potently
blocks both Ito and IK,ACh, and also modulates IKr and IKs,
exhibiting multiple K+-current block. The parameters of Hill
equations describing use-dependent inhibitions of these channels
by acacetin are shown in Table 1. In the simulations, the effects
of acacetin on these channels were modeled using a simple pore
block model (Yuan et al., 2015). In the present study, we did not
simulate the effects of acacetin on IK,ACh inhibitions as the role of
autonomic regulation on AF is beyond the scope of the study.
Simulations of the Effects of Acacetin on Human
Ventricle
The effects of acacetin on human ventricular APs are unknown,
although experimental data demonstrated that acacetin at 30µM
did not affect the heart rate and QT interval in isolated rabbit
hearts (Li et al., 2008). In the present study, it was assumed
that similar effects on the K+ currents (Ito, IKr, IKs) in atrial
myocytes could be extrapolated to the ventricular myocytes. We
acknowledge that IKur is negligible in ventricles (Ravens and
Wettwer, 2011), therefore in simulations of blocking IKur alone,
the ventricular electrophysiology was not affected.
Tissue Models
The effects of acacetin and INa blockers on atrial and ventricular
electrophysiology were further evaluated using tissue models.
The monodomain equation (Clayton et al., 2011) was employed
to simulate the excitation wave propagation in the myocardium.
1D models of human atrial strands were used to quantify the
effects of channel blockers on atrial conduction velocity and APD
restitution properties. Changes in ventricular depolarization and
repolarization in response to these drugs were evaluated using
a 1D model representing a transmural strand of ventricular
tissue. In order to evaluate the antiarrhythmic effects of the
channel blockers on re-entrant excitations in atria in the setting of
cAF-induced remodeling, both idealized 2Dmodels representing
an isotropic slab of atrial tissue and an anatomically accurate
3D model of the human atria (Aslanidi et al., 2011; Colman
et al., 2013, 2017; Whittaker et al., 2017) were employed to
simulate the behavior of re-entrant excitations in atrial tissue.
Pseudo-ECGs (pECGs) (Gima and Rudy, 2002; Baher et al.,
2006) were computed as a measure of the excitation rates of in-
tissue with sprial excitation waves. Detailed descriptions of these
tissue models and pECGs are given in Online Supplementary
Material 1.2, 1.3.
RESULTS
The updated Colman et al. human atrial model was first
used to simulate effects cAF-induced remodeling on the
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FIGURE 1 | Frequency-dependent inhibition of IKur by acacetin. (A) Experimental and (B) simulated traces of KV1.5 channel current elicited from the 20th voltage
step repeating at 0.5 and 4Hz in control (left) and after exposure to 3µM of acacetin (right). (C) Relative remaining IKur following application of acacetin at various
frequencies plotted against the pulse number of the voltage step. The simulated data (lines) were compared with experimental values (squares). The relative fraction
was obtained by normalizing the end-step current measured from each pulse following application of acacetin to that of control. Experimental data were digitalized
from Wu et al. (2011).
action potential (AP) and calcium transient (CaT). Details
are presented in Online Supplementary Material 2.1.
The resultant changes in APD, APD restitution and CaT
following cAF-induced remodeling as compared to those
under the normal condition showed good agreement with
previous experimental (Bosch et al., 1999; Osaka et al., 2000;
Workman et al., 2001; Dobrev and Ravens, 2003; Voigt et al.,
2012) and simulation studies (Zhang et al., 2005; Grandi
et al., 2011; Colman et al., 2013, 2017; Wilhelms et al.,
2013).
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Effects of Application of Acacetin on
Human Atrial Cells
To reveal the roles of inhibition of individual channels
by acacetin in modulating cellular AP by acacetin, both
the individual and combined block of Ito, IKr, IKur,
and IKs by acacetin (3.2µM) in simulated SR at cycle
length 1,000ms without (normal) or with cAF-related
electrical remodeling were simulated. Figures 2A,B
illustrates the effects of individual and combined K+-
channel block by acacetin on AP waveform. The alterations
to APD relative to the control are summarized in
Figures 2C,D.
FIGURE 2 | Effects of individual vs. combined block of K+-currents by acacetin (3.2µM) on the human atrial AP in normal and cAF-remodeled myocytes paced at
1Hz. (A,B) Effects on the atrial AP in (A) normal and (B) cAF-remodeled myocytes; a zoomed-in view for the traces of AP during phase-3 is plotted to the right.
(C,D) Alterations in the (i) APD90 and (ii) APD30 by the simulated block obtained from atrial cells in (C) normal and (D) cAF-remodeled myocytes.
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In the absence of electrical remodeling, in normal myocytes
at a cycle length of 1,000ms, simulated IKs or IKr block by
acacetin (3.2µM) presented no significant alterations to the atrial
AP: although the atrial repolarization was delayed by 1.3 and
5.9ms, respectively, the plateau phase was not affected, which
is consistent with the minimal potency of acacetin on these
channels (Table 1). Similar effects were also obtained from our
simulated IKr and IKs block by the compound in the cAF-
remodeled atrial cells.
Selective block of Ito (alone) by acacetin elevated the atrial
plateau potential in both normal and cAF-remodeled myocytes
paced at 1Hz, and this led to modest prolongations in APD30
(by 6.4 and 3.6ms for normal and AF-remodeling myocytes,
respectively). The changes in APD90 due to Ito block varied
between the two conditions: under normal conditions the atrial
APD90 was shortened by 2.4ms, whereas it was prolonged by
3.7ms following cAF-remodeling at a stimulus rate of 1Hz.
In contrast, blocking IKur alone by acacetin resulted in a
pronounced alteration to the shape and duration of the AP
in both normal and cAF-remodeled myocytes. The inhibition
in IKur significantly elevated the plateau potential of atrial
AP (by 7.1 and 5.7mV in normal and cAF-remodeled
myocytes, respectively), and this was accompanied by marked
prolongations in APD30 (by 105.9 and 23.6ms in normal
and cAF-remodeled myocytes, respectively). The prolongation
in APD90 induced by the IKur block was 9.8ms for normal
atrial cells, and was more pronounced (23.6ms) in cAF-
remodeled myocytes, despite that IKur was down-regulated by
cAF-remodeling.
We note that combined effects of acacetin (3.2µM) on
multiple K+-currents produced greater alterations to the AP than
those of any individual blocking effect. We have quantified effects
produced by the combined block and compared it with the sum
of the changes seen in each individual block. Synergistic effects
were observed in the changes in APD90, represented by a further
prolongation of 9.3 and 1.1ms in APD90 in normal and cAF-
remodeledmyocytes, respectively. Additionally, the effects of IKur
block dominated the AP-modulation by the compound, which
is consistent with the high potency of acacetin on the channel
(Table 1).
Effects of Sodium Blocker and Acacetin on
cAF-Remodeled Atrial Myocytes and
Ventricular Cells
Effects on Single Myocyte AP and INa
Individual and combined effects of Na+-block (indicated by
Bl·INa) and K
+-block by acacetin (3.2µM) on human atrial
electrophysiology after cAF-remodeling were simulated to assess
any anti-AF benefits. Effects of acacetin (representing K+-block)
were simulated in different settings: (i) IKur block alone (denoted
by Bl·IKur) and (ii) combined block of all K
+-currents in Table 1
(denoted by Comb·Bl·IX). In addition, the effects of Na
+- and
K+- block on human ventricular myocytes were also studied to
assess the atrial-selectivity of the block. The results are shown
in Figures 3A–C and quantitative measurements are shown in
Figures 4A–C.
For atrial myocytes paced at 1Hz, Bl·IKur, and Comb·Bl·IX
prolonged atrial APD (Figure 4Ai and as presented in Effects
of Application of Acacetin on Human Atrial Cells) whilst their
effects on peak INa were minimal (reducing peak INa by less
than 0.3%). Bl·INa alone slightly reduced the peak INa by 1.63%
without affecting the APD. The fractional inhibition in INa
by INa-block was slightly increased by the addition of Bl·IKur
or Comb·Bl·IX (Figure 4Aii). In the ventricles, the simulated
application of acacetin induced a prolongation of 19.5ms in
APD90 compared with that in control (drug-free) condition
(Figures 3B, 4Ci). Bl·INa alone showed a negligible inhibitory
effect on the ventricular INa (by 0.42%), which was also not
affected by combining Bl·INa and Comb·Bl·IX (Figure 4Cii).
In atrial myocytes paced at 6Hz, AP alternans were observed
under the drug-free condition (Figure 3Ci): the APD varied
between 100.1 and 88.1ms. In the presence of AP alternans, the
changes in APD by the Na+- and K+- blockers were quantified by
comparing the corresponding big APs at baseline and after drug
actions. These values were selected based on the characteristics
of AP (APD prolongations seen in the long AP, and reduced INa
for the short AP) that may be anti-arrhythmic. The fractional
reductions in peak INa were calculated from the INa associated
with the shorter APs. The results showed that applying Bl·IKur
or Comb·Bl·IX alone both abolished the AP alternans while
prolonging the APD to 116.3 and 126.3ms and reducing the peak
INa by 5.9 and 20.1%, respectively. The application of Bl·INa alone
produced a minor APD prolongation (3.5ms) and a reduction
of 16.2% in peak INa. Combining block of INa with Bl·IKur or
Comb·Bl·IX promoted the genesis of AP alternans, resulting in
substantial prolongations in the APD of the big APs (by 35.4ms
for Bl·IKur + Bl·INa, and 55.6ms for Comb·Bl·IX + Bl·INa) and
dramatic decreases in the peak INa (by 57.5% for Bl·IKur + Bl·INa
and 88.2% for Comb·Bl·IX + Bl·INa) in the corresponding small
APs. These results suggest that the combined block of Bl·INa and
Comb·Bl·IX/Bl·IKur exhibited synergistic antiarrhythmic effects
manifested by prolongation in APD and reduction in peak
INa. However, an increased susceptibility to AP alternans was
observed at a fast pacing rate of 6Hz, which may be potentially
proarrhythmic at fast heart rates.
Effects on Steady-State Restitutions of APD and
Conduction Velocity
Steady-state APD restitutions of cAF-remodeled human atria
were simulated at both the cellular and tissue levels. In
single myocyte simulations (Figure S5 in Online Supplementary
Material 2.2), APD was prolonged over the entire range of
simulated basic cycle lengths (BCL) for Bl·IKur and Comb·Bl·IX
as compared to the control (drug-free) conditions. The reduction
in peak INa in Bl·INa was rate-dependent and significantly greater
at fast pacing rates. K+-block alone (Bl·IKur or Comb·Bl·IX)
slightly shifted the rate-dependence of peak INa to larger BCLs. In
comparison to the effects of individual current block scenarios,
synergistic reductions in peak INa were observed following
combined blocks of Bl·INa with Bl·IKur or Comb·Bl·IX over a
wide range of BCLs. As compared to the drug-free conditions,
AP alternans were observed at greater BCLs after K+-block,
and this was further increased by combined Na+- and K+-block
(Figure S5 in Online Supplementary Material 2.2).
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FIGURE 3 | Simulated AP and INa traces of cAF-remodeled atrial myocytes and ventricular cells in response to Na
+- and K+- block regimens. (Ai) APs from
cAF-remodeled atrial myocytes paced at 1Hz; (Aii) Time courses of corresponding INa during the upstroke phase. (B) Simulated time courses of AP and INa of a
ventricular cell paced at 1Hz. (C) Illustration of (i) APs and (ii) the corresponding time courses of INa of a cAF-remodeled myocyte paced at 6Hz. In these simulations,
rate constants for INa blocker were: KA = 100 ms
−1
· M−1, KI = 100 ms
−1
· M−1, IA = 1 ms
−1, II = 0.01 ms
−1.
Using a 1D model of atrial strands, the atrial APD
and conduction velocity (CV) restitutions, as well as
the rate-adaptation of in-tissue upstroke velocity (Vmax),
were evaluated (Figure 5). The atrial activation-recovery
interval (ARI) was not affected by Bl·INa alone, whereas
it was substantially lengthened by K+-block as compared
to control (Figure 5A). Applying K+-block alone also
shifted the CV and Vmax restitution curves rightwards (i.e.,
to higher BCLs) (Figures 5B,C). These rate-adaptations
of Vmax and CV were progressively enhanced by Bl·INa
and the combined block over a wide range of BCLs.
Synergistically enhanced rate-dependent reductions in
Vmax and CV were observed in response to the combined
blocks. Furthermore, K+-block increased the critical BCLs
for conduction block as compared to the drug-free condition
(Figure 5C).
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FIGURE 4 | Simulated changes in the APD and peak INa following the applications of Na
+- and K+- block in comparison to the drug-free condition in cAF-remodeled
atrial myocytes or ventricular cells. (A,B) Changes in (i) APD and (ii) peak INa measured from a cAF-remodeled atrial myocyte paced at (A) 1Hz and (B) 6Hz. In the
presence of alternans, the changes in APD were quantified by comparing the corresponding longer APs. The fractional reductions in peak INa were calculated from
the INa of the corresponding shorter APs. (C) Changes in (i) APD and (ii) peak INa measured from an in silico ventricular myocyte paced at 1Hz.
Effects of Combined Na+- and K+- Block
on the AF-Selectivity of INa block
AF-selectivity of Na+ blockers in cAF-remodeled hearts was
examined by varying the drug binding and unbinding constants
over wide parameters spaces to provide information concerning
drug-Na+-channel interactions for various drug candidates. This
was done by independently changing LA and LI for fixed {KA,KI}
(Online Supplementary Material 2.3); and then varying KA and
KI for fixed {LA, LI}. In this way we obtained the maximum
AF-selectivity over the parameter space of drug binding and
unbinding kinetics. Simulations with varied KA and KI were
repeated for Bl·INa + Bl·IKur and Bl·INa + Comb·Bl·IX.
Figures 6A–D illustrates the block efficacy (defined in
Equation 4), rate-selectivity, atrial-selectivity and the resultant
AF-selectivity for Bl·INa alone and the combined block as a
function of KA and KI . For Bl·INa alone, the block efficacy
increased with increase of KI, whereas the rate-selectivity was
reduced by increasing KA or KI . The AF-selectivity reached a
maximum value of 9 at KA = 1 and KI = 500 ms
−1
· M−1.
The combined blocks achieved significantly greater AF-selectivity
than Bl·INa alone: the maximum attainable AF-selectivity was
increased by nearly 6-fold for Bl·IKur + Bl·INa and more
than 14-fold for Comb·Bl·IX + Bl·INa as compared to Bl·INa
alone (Figure 6C). These dramatic increases were attributed
to the significantly greater values in all metrics contributing
to the AF-selectivity. The maximal block efficacy achieved by
Bl·INa alone was 0.77, and was increased to 0.81 and 0.94
for Bl·IKur + Bl·INa and Comb·Bl·IX + Bl·INa, respectively. A
more appreciable increase in the maximal rate-selectivity was
observed by the combined blocks as compared to Bl·INa alone
(8-fold for Bl·IKur + Bl·INa and nearly 10-fold for Comb·Bl·IX +
Bl·INa). Additionally, the atrial-selectivity was also increased by
the combined block, although to a lesser extent. Bl·IKur + Bl·INa
exhibited a greater atrial-selectivity than that of Comb·Bl·IX
+ Bl·INa since Bl·IKur was assumed to have no effect on the
ventricles.
Furthermore, these simulations revealed that the block
efficacy, rate-selectivity and atrial-selectivity were strongly
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FIGURE 5 | Simulated activation-recovery intervals (ARI) (A), Vmax (B), and CV (conduction velocity) (C) measured in 1D cAF-remodeled atrial strand models as a
function of BCL for control (drug-free), individual and combined Na+- and (i) IKur block and (ii) action of acacetin. ARI values were measured as the interval between
the time at which the AP depolarizes to −20mV and the time it reaches a 90% repolarization.
dependent on the inactivation state binding rate KI . These
measures were also dependent on the open-state binding kinetics
KA, but to a much lesser extent. The block efficacy was mainly
determined by KI : an increase in KI led to a significant increase
in the block efficacy. In combined block, the maximal rate- and
atrial-selectivity were observed for KA = KI = 1 ms
−1
·
M−1 and increases in KI resulted in substantial reductions in
the rate- and atrial-selectivity. In Bl·INa alone, the parameter
set KA = 1 ms
−1
· M−1, KI = 200 ms
−1
· M−1 produced
a maximal value in atrial-selectivity. Collectively, the optimal
KI that maximized AF-selectivity was 200 ms
−1
· M−1 for
Bl·INa and Bl·IKur + Bl·INa, and smaller (100 ms
−1
· M−1)
for Comb·Bl·IX + Bl·INa. The optimal KA = 1 ms
−1
· M−1
was seen for all conditions. Increasing KA consistently resulted
in a smaller rate- and atrial-selectivity and therefore reduced
AF-selectivity. These results suggest that the inactivation-state
binding rate might be a more favorable targeting parameter than
the open-state binding kinetics in optimizing AF-selectivity of
Na+-blockers.
Effects of INa and IKur Block on Spiral
Excitation Events in cAF-Remodeled Atria
Two-Dimensional Simulations
Using the cross-shock protocol, spiral waves were initiated in a
2D model representing a tissue slab of cAF-remodeled human
atria. For each condition, a 10-s episode of electrical activity
was simulated. Representative snapshots of the re-entrant waves
in control (drug-free) and following application of drugs are
presented in Figure 7A. The trajectories of the tips of re-entrant
rotors under these conditions were traced and are shown in
Figure 7B. The number of rotors during the time course of wave
evolution was also measured (Figure 7C). The simulated pseudo-
ECGs, membrane potential traces extracted from a representative
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FIGURE 6 | Block efficacy, and the rate-, atrial-, and AF-selectivity as a function of the open- and inactivated- state binding rates (KA,KI ) for Na
+-block or combined
Na+- and K+-block computed from cAF-remodeled atrial myocytes or ventricular myocytes. (A) Block efficacy; (B) rate-selectivity; (C) atrial-selectivity, and (D)
AF-selectivity. In each column shown are data from Bl·INa (i), combined Bl·INa and Bl·IKur (ii), and combined Bl·INa and Comb·Bl·IX (iii).
LA = 1 ms
−1, LI = 0.01 ms
−1. Unit of KA,KI: ms
−1
·M−1.
myocyte and the corresponding fractional block of INa and IKur
are detailed in Online Supplementary Material 2.4.
Under the control (drug-free) condition, a single rotor was
formed at approximately t = 630ms; this broke into two spiral
waves at t = 830ms. These two rotors were stably anchored
with star-shaped tip trajectories at the bottom half of the slab
and persisted throughout the rest of the simulated 10-s episode
(Figures 7Ai,Bi,C). In simulating drug actions, each drug was
applied at t = 2,500ms. For Bl·INa the dual rotors progressively
became unstable, and the tips of the spiral waves meandered
out of the tissue at approximately t = 6,000ms, leading to self-
termination of the re-entrant waves (Figures 7Aii,Bii,C). The
dual rotors persisted throughout the period of the simulation
after applying Bl·IKur alone (Figures 7Aiii,Biii,C). For Bl·INa +
Bl·IKur, the rotor at the bottom left corner of the slab became
unstable and meandered out of the tissue at approximately t
= 3,800ms, whereas the trajectory of the second rotor was
confined to a small tissue area until t = 7,000ms and then
gradually became chaotic, forming up to 3 transient rotors
that self-terminated at t = 8,334ms (Figures 7Aiv,Biv,C). A
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FIGURE 7 | Snapshots of simulated re-entrant excitation events, tip trajectories of re-entrant waves and the number of rotor in a 2D model of cAF-remodeled atrial
tissue slab in drug-free condition or after applying the drugs. (A) Snapshots of simulated re-entrant excitation events; The time sequence (ms) is indicated at the top
left corner of each screenshot. (B) Tip trajectories of re-entrant waves. (C) Temporal evolution of total number of rotors represented by the number of spiral wave tips
in tissue. In both (A,B), (i) Drug-free (CTL) condition, (ii) Bl·INa alone, (iii) Bl·IKur alone, (iv) Combined Bl·INa and Bl·IKur, (v) Applying Comb·Bl·IX alone, and (vi)
Combined Bl·INa and Comb·Bl·IX. Rate constants for INa block: KA = 1 ms
−1
·M−1,KI = 100 ms
−1
·M−1, LA = 1 ms
−1, LI = 0.01 ms
−1.
similar but more marked effect was seen in the simulations
that addressed the aggregate effects of acacetin: the bottom
left rotor quickly meandered out of the tissue at t = 3,510ms
whilst the tip trajectory of the other rotor became chaotic and
terminated at t = 5,439ms (Figures 7Av,Bv,C). We note that the
combined Bl·INa and Comb·Bl·IX exerted the strongest potency
in terminating re-entrant excitations in these simulations: the
two rotors transiently turned unstable and chaotic and self-
terminated at t = 3,555ms, with up to 5 rotors during the
excitation in the slab (Figures 7Avi,Bvi,C).
The anti-arrhythmic benefits of combined Na+- and K+-
block were clearly revealed by additional simulations assuming
the use of a different Na+-blocker (KA = 1 ms
−1
· M−1,KI =
200 ms−1 ·M−1, LA = 1 ms
−1, LI = 0.01 ms
−1) and at a reduced
dose (75%) of both Na+-blocker and acacetin. The life span of re-
entrant excitations was measured and shown in Figure 8A. Also,
the pECG was computed and the segment from t = 3,000ms to
500ms before the termination of re-entries (or the end of the
simulation if the rotor sustained) was analyzed using the Fast
Fourier Transform to obtain the dominant frequency (DF) of the
re-entrant excitations, which is illustrated in Figure 8B.
At the simulated doses of acacetin, applying Bl·IKur alone did
not lead to termination of re-entrant waves within the duration
of the simulation (7,500ms after TDrug), whereas the rotors were
terminated in the simulations for Comb·Bl·IX at both doses
(Figure 8Ai–iv), thus demonstrating enhanced anti-AF benefits
of combined K+-channel block. For the simulated Bl·INa alone,
the Na+-blocker with KI = 100 ms
−1
· M−1 led to termination
of AF at the control dose (lifespan of 4,102ms) but not at the
reduced dose; increasingKI of the Na
+-blocker to 200ms−1·M−1
resulted in a reduced lifespan (1,305 and 1,459ms for [DNa+ ] =
60 and 45 µM, respectively). The lifespan for the combined
Bl·INa + Comb·Bl·IX was consistently shorter than that of any
individual applications of Bl·INa or Comb·Bl·IX alone in all cases.
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A similar augmented anti-arrhythmic effect (shown as shortened
lifespan of re-entry) was also observed for the combined Bl·INa
+ Bl·IKur for [DNa+ ] = 45 µM and KI = 200 ms
−1
· M−1
(Figure 8Aiv) but not for the rest of the cases.
A consistent decrease in the DF was observed in the drug-
modulated re-entrant excitations as compared to those in the
drug-free condition (Figure 8Bi–iv). In the drug-free condition,
the DF extracted from the pECG was 8.63Hz, which is within
the range of similar clinical data (Jarman et al., 2012). Applying
Na+- or K+- block individually resulted in slowing of the rate
of the rotors, and this was dependent on the concentrations
and parameters of the blockers. For Bl·IKur the DF was 8.25Hz
FIGURE 8 | Dominant frequency and lifespan of re-entrant waves in 2D simulations using the cAF-remodeled atrial tissue model in the drug-free condition or after
applying drugs. (A) Lifespan of the spiral waves. (B) DF of spiral waves. The results of K+-block alone are shown in both left and right panels for the purpose of
comparison. In the left column (i,iii) of (A,B), Bl·INa was simulated with KI = 100 ms
−1
·M−1; in the right column (ii,iv), KI = 200 ms
−1
·M−1. In the top panels (i,ii)
of (A,B), [DK+ ] = 3.2µM, [DNa+ ] = 60µM; in the bottom panels (iii,iv), [DK+ ] = 2.4µM, [DNa+ ] = 45 µM. In all panels, KA = 1 ms
−1
·M−1,
LA = 1 ms
−1, LI = 0.01 ms
−1.
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with the control dose and 8.30Hz for the reduced dose. In the
simulations with Comb·Bl·IX, the DF was 6.63Hz and was not
affected by the 25% reduction in the dose of the compound.
For Bl·INa alone the DF was 7.81Hz and substantially smaller
(6.24Hz) for Na+-blockers of KI = 100 ms
−1
· M−1 and KI =
200 ms−1 · M−1, respectively. An enhanced deceleration of the
rotors was observed for Bl·INa + Bl·IKur in all cases. The DF for
simulations with Comb·Bl·IX + Bl·INa was not computed due to
the short lifespan in these events.
3D Simulations
The antiarrhythmic effects of acacetin and Na+-block on the re-
entrant waves in the cAF-remodeled atria were also evaluated
using our 3D anatomicalmodel of the human atria (Colman et al.,
2013, 2017). A 10-s episode of sustained re-entrant excitation
was first initiated in the cAF-remodeled atria in the drug-
free condition; this produced the initial conditions of the 3D
model for additional 10-s episode simulations. Next, the behavior
of electrical waves of another 10-s episode simulation in the
drug-free condition and after applying the selected blockers
was analyzed and compared. Figure 9A shows snapshots of
excitation wave evolution following the 10-s episode of re-entrant
excitation events. pECGs computed from the excitation waves
are shown in Figure 9Bi–iv. Figures 9C,D illustrates power
spectrum analyses of the pECGs and a comparison of the lifespan
of the electrical waves in the drug-free condition and after
applying the drugs/blockers. In the drug-free condition, stable re-
entrant waves around the pulmonary veins and left atrium were
observed; the power spectrum density (PSD) manifests a single-
focused peak around 8.16Hz. Following applying Bl·INa, the re-
entrant waves became less organized and also decelerated. This
was characterized by a smaller dominant frequency (6.58Hz) and
less focused PSD distribution; the excitation was not terminated.
Following the application of Comb·Bl·IX, the re-entrant wave
soon became unstable and eventually disappeared after t =
3,279ms. Note that the peak PSD amplitude was much smaller
and its distribution was much broader as compared to the
drug-free condition. The combined drugs further destabilized
the re-entrant waves and reduced the lifespan to approximately
1,120ms.
Simulated Effects of Acacetin and
Na+-Current Blocker on the QT Interval
Further simulations were performed using a 1D ventricular
transmural strand model to evaluate the changes in the
waveform of electrograms in consequence of applying the drugs.
A comparison of the computed electrogram waveforms are
illustrated in Figures 10A,B, and the QT intervals are quantified
in Figure 10C. Blocking small fractions of IKr, IKs and Ito in the
human ventricles by acacetin slightly increased the QT interval
by 21ms. The electrograms were not noticeably affected by
applications of the Na+-blocker with the simulated parameters.
Results from both cases did not show dramatic QT prolongation,
indicating no dramatic effects affecting ventricular repolarization
process which might promote ventricular arrhythmias.
DISCUSSION
Even decades after goal-directed work, successful development
of effective and safe antiarrhythmic drugs for treating AF has not
been accomplished and remains a major unmet clinical need. In
a recent study on the canine heart, enhanced anti-arrhythmic
effects and AF-selectivity of INa blockade by additional IKur
block was demonstrated (Aguilar et al., 2015). Whether similar
effects could be obtained in the human atria, especially following
cAF-induced electrical remodeling which reduces IKur, remained
unclear. How the combined Na+ and K+-block modulates the
QT interval also remained incompletely understood. In this
study, the effects of IKur (combined with a modest block in Ito,
IKr, and IKs as presented by acacetin, a compound shown to be
effective in anti-AF treatment) and INa block (two potentially
effective atrial-selective block on human atrial electrophysiology)
were investigated in silico using multiscale models of the human
atria and state-dependent block scheme. The simulation results
demonstrate that both Na+-block and K+-block exhibited
anti-arrhythmic effects in the atria following cAF-remodeling,
despite reduced IKur by the remodeling. The present study
highlighted that in addition to combined Na+- and K+-block,
combined multi-K+-channels also exerted beneficial synergistic
antiarrhythmic effects when compared with single channel block
whilst having modest impact on ventricular repolarization (QT
interval). This study suggests that multi-channel block (either
combined Na+-K+-block, or combined multi-K+-block) may be
a favorable strategy for the development of novel pharmaceutical
therapies for AF.
Effects of INa block
An atrial-ventricular difference in the properties of INa, especially
in the voltage dependence of steady-state inactivation, has been
reported (Li et al., 2002; Burashnikov et al., 2007; Chen et al.,
2016; Fan et al., 2016; Caves et al., 2017). In these studies,
the voltage dependent steady-state inactivation curves for INa
were found to be negatively shifted (by 5–16mV) in atrium as
compared to the ventricular parameters. This difference gave
rise to an on-going interest in developing an atrial-selective
blocker of INa as a strategy in terminating AF (Burashnikov et al.,
2007; Antzelevitch and Burashnikov, 2009; Zygmunt et al., 2011;
Morotti et al., 2016; Caves et al., 2017). As was done in previous
studies (Aguilar-Shardonofsky et al., 2012; Aguilar et al., 2015),
in this study, the kinetic parameters in drug actions of Na+-
blockers were varied over wide parameter spaces to reveal AF-
selectivity of Na+-blockers in the ventricles and fibrillating atria.
Our results demonstrated that in the presence of AF-remodeling,
an atrial-selective block of INa could produce different effects
between atrial and ventricular cells (Figures 3, 4) and that the
AF-selectivity could bemaximized by optimizing the binding and
unbinding rates of the Na+-blocker (Figure 6). Note also that,
the fractional inhibition of INa by the Na
+-blocker exhibited a
substantial dependence on the rate of pacing (Figures 3, 4 and
Online Supplementary Material 2.2), which was quantified using
the rate-selectivity (Figure 6).
At the cellular level, Na+-block resulted in a significant
inhibition in INa at fast pacing rates, but minor effects within
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FIGURE 9 | Simulated re-entrant excitations computed using the 3D anatomical model of the cAF-remodeled human atria in response to application of channel
blockers as compared to that of the drug-free (CTL) condition. (A) Snapshots of electrical excitation waves. Drugs were applied at t = 0ms. (B) Simulated pECGs.
(C) Power spectrum density (PSD) obtained from the pECGs. PSDs were normalized to the maximum value of that in control. (D) Lifespan of re-entrant excitations in
these simulated atria for various conditions. The symbol∞ indicates the spiral waves were sustained throughout the 10-s episode of simulation.
KA = 1 ms
−1
·M−1, KI = 100 ms
−1
·M−1, LA = 1ms
−1, LI = 0.01 ms
−1; [DK+ ] = 3.2µM, [DNa+ ] = 60µM.
the range of normal heart rates in the atria (Figures 5, 6). The
antiarrhythmic effects of these changes were demonstrated in
simulations of multicellular atrial tissue. In a 1D atrial strand
model, applying Na+-block progressively enhanced the rate-
adaptations of Vmax and CV over a larger range of BCLs, whereas
the atrial APD was not affected. At fast pacing rates, Vmax and
CVwere decreased significantly, suggesting reduced excitabilities
of atrial myocytes (Figure 5). These results are in concordance
with the recent study (Aguilar et al., 2015) where similar effects
of Na+-block on the canine atria were demonstrated in silico and
experimentally in coronary-perfused hearts.
In 2D tissue simulations, this Na+-block shortened the
lifespan and caused slowing in the excitation rate of the
spiral waves (Figures 7, 8). In the 3D anatomical model,
applying Na+-block alone produced antiarrhythmic effects by
slowing the re-entrant excitations (Figure 9). Furthermore,
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FIGURE 10 | Computed pECGs from a 1D strand model for human ventricular transmural strands in drug-free (CTL) condition and in response to anti-arrhythmic
drugs. In (A,B) two sets of parameters (#1 KI = 100 ms
−1
·M−1, #2 KI = 200 ms
−1
·M−1 ) for INa block were simulated. (C) QT intervals measured from the pECGs.
in our 1D model of transmural ventricular strand, the
simulations suggested that the Na+-block had minimal impact
on ventricular repolarization, as judged by modest QT interval
prolongation. These results demonstrated that Na+-block
could be beneficial in suppressing re-entrant activities in
the cAF-remodeled atria, with modest impact on ventricular
repolarization.
Effects of K+-Current Block
K+-current blockers delay the repolarization phase of the AP
and thus prolong atrial APD and refractory period. This can
cause disruptions and eventually termination of the re-entrant
circuits (Hancox et al., 2016). However, K+-channel blockers
such as dofetilide and sotalol (which potently inhibit IKr) have
a substantial risk of prolonging QT interval and promoting
Torsades de pointes arrhythmias (Hondeghem and Snyders, 1990;
Yap and Camm, 2003). In principle, blocking atrial-specific K+-
channels may exert antiarrhythmic effects in the atria while
minimizing potential risks of adverse effects in the ventricles.
IKur is believed to be such an atrial-selective substrate for drug
interventions, and effects of IKur block have been extensively
studied (Burashnikov and Antzelevitch, 2008; Li et al., 2008;
Tsujimae et al., 2008; Almquist et al., 2010; Pavri et al., 2012;
Scholz et al., 2013; Loose et al., 2014; Ford et al., 2016).
Interestingly, many existing IKur blockers potently block other
K+-channels including Ito and IK,ACh (Gögelein et al., 2004;
Wirth et al., 2007; Burashnikov and Antzelevitch, 2008; Li et al.,
2008). The additional blockades of these channels may contribute
to the antiarrhythmic effects of those drugs, which warrant
further investigations.
In this study, acacetin, a compound initially isolated from
the traditional Chinese medicine Xuelianhua, was selected as
a representative IKur blocker. The effects of acacetin on atrial
electrophysiology were evaluated in two ways: (a) the effects of
acacetin blocking IKur only; and (b) the full actions of acacetin on
the targeting channels (Ito, IKur, IKr, and IKs) (Li et al., 2008). This
approach allowed for investigations into the effects of IKur block
alone as well as the potential benefits of additional-but-modest
inhibition of other K+-currents in the human atria.
Selective IKur Block
Blocking IKur with 3.2µM acacetin exerted APD prolongation
(9.8ms) under the baseline/normal conditions (Figure 2).
Experimental data show that dependent on the baseline AP
waveform the effect of IKur block on human atrial APD70−90
under normal (SR) conditions can manifest as prolongation or
shortening in the APD, (Workman et al., 2001; Wettwer et al.,
2004; Schotten et al., 2007; Burashnikov and Antzelevitch, 2008;
Loose et al., 2014). Additionally, the prolongation in APD by IKur
block observed in the present study is similar to our previous
paper (Colman et al., 2017) concerning the effects of genetically
down-regulated IKur. Moreover, inhibiting IKur under normal
conditions elevated the AP plateau potential and prolonged
APD30 (Figure 2). Both effects matched well with experimental
studies (Workman et al., 2001; Wettwer et al., 2004; Schotten
et al., 2007; Burashnikov and Antzelevitch, 2008; Loose et al.,
2014) and our simulation study (Colman et al., 2017).
We note that in the cAF-remodeling cells, a more pronounced
prolongation in APD (by 23.6ms for 1Hz and 16.2ms at 6Hz,
Figure 4) was observed in the presence of 3.2µM acacetin,
despite that this current was down-regulated by cAF-remodeling
(Wagoner et al., 1997; Brandt et al., 2000; Christ et al., 2008).
These results are in accordance with previous experimental
results of blocking IKur with MK-0448 (Pavri et al., 2012; Loose
et al., 2014). In addition, IKur block exhibited enhanced rate-
dependent adaptations in APD both at the cellular (Online
Supplementary Material 2.2) and 1D strand models (Figure 5).
Importantly, the CV restitution curve shifted toward higher
BCLs, indicating that this tissue is less capable of conduction of
atrial excitation waves at high rate while maintaining conduction
of slow waves (Figure 5). In 2D tissue simulations, applying IKur
block alone (3.2µM acacetin) destabilized the cores of rotors
(i.e., potential organizing centers for AF), and slightly slowed
their excitation rates, but failed to terminate them (Figure 7),
suggesting a limited efficacy of terminating AF by IKur block
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alone. Similarly, a recent modeling study by Aguilar et al. (2017)
suggested that the antiarrhythmic efficacy of IKur block was
substantially decreased in the presence of AF-induced electrical
remodeling. Also, the experimental study (Burashnikov and
Antzelevitch, 2008) showed that block of IKur by 4-AP of small
doses had limited efficacy in suppressing AF in canine atria. This
may represent the fact that IKur is reduced at high frequencies
(as discussed/suggested in Feng et al., 1998a; Burashnikov and
Antzelevitch, 2008; Wu et al., 2011) and shown in Figure 1)
as well as by cAF-induced remodeling (Wagoner et al., 1997;
Brandt et al., 2000; Christ et al., 2008). In addition, IKur is
primarily active during phase 2 of AP, and hence pure IKur block
exerted a relatively greater prolongation in APD30 than APD90
(Figure 3), in contrast to other K+-block including dofetilide
which mediates anti-AF effects by prolonging the terminal phase
of the AP (Roukoz and Saliba, 2007).
In this study, IKur block was simulated using a state-dependent
block model, which successfully reproduced the use- and rate-
dependent inhibition of acacetin (Figure 1). The rate-dependent
block of IKur exerted a higher fractional inhibition in the
current at faster pacing rates, which likely produces greater
anti-AF effects in the presence of high-frequency excitations as
seen during AF. Along with the previous modeling studies on
investigating effects of IKur block (Almquist et al., 2010; Scholz
et al., 2013; Ellinwood et al., 2017), this study demonstrated
the importance of explicitly considering the kinetic properties
of the block in computational efforts of understanding the
consequences and underlying mechanisms of IKur block.
Effects of Combined K+-Current Block
The combined K+-block (as exhibited by acacetin and many
other IKur blockers) resulted in synergistic APD prolongation as
well as an increased efficacy in terminating re-entry in tissue as
compared to the pure IKur block.
Note that at the single myocyte level, the combined actions
of acacetin produced greater prolongation in atrial APD than
the sum of changes due to drug-induced block of individual
channel in normal and cAF-remodeled myocytes (Figure 2).
Additionally, the combined K+-block increased the rate-
additivity of APD as compared to the pure IKur block (Online
Supplementary Material 2.2). This was also consistently observed
in the 1D simulation (Figure 5). In the setting of pure IKur
block, the elevated and prolonged plateau phase of the AP
could promote the activation of IKr/IKs, which in return may
accelerate the repolarization of AP-phase 3 (Colman et al., 2017).
Therefore, additional inhibition in IKr by an identical fraction
is expected to result in a greater APD prolongation than a pure
IKur or IKr/IKs block.
In 2D simulations, the combined K+-block produced an
enhanced efficacy in suppressing AF compared with the pure
IKur block: promoting meandering of rotor tips (Figure 7B),
shortening the lifespan of re-entries (Figure 8A) and slowing
of spiral wave excitations (Figure 8B). Rotor meandering is one
mechanism by which spiral waves may meet non-conducting
boundaries to extinguish re-entry (Narayan et al., 2013; Pandit
and Jalife, 2013; Rappel et al., 2015).
The effects of acacetin (3.2µM) on the ventricular AP
and QT interval was assessed in a single cell model and 1D
transmural strand model by assuming similar blockade effects of
the compound on the human ventricles and atria. It was shown
that following applying acacetin, the ventricular repolarization
and QT interval was both preserved with slight prolongations
around 21ms (Figure 10). Our results are close to the previous
experimental study (Li et al., 2008) showing that QT intervals
were not prolonged by acacetin in isolated rabbit hearts and
anesthetised dogs.
The synergistic effects demonstrated by the combined K+-
blocks have implications on developing novel pharmaceutical
anti-AF therapies. Given that Ito, IKr and IKs contribute to the
repolarizations of ventricular APs, inhibitions in these channels
may promote risks of side effects in the ventricles. In this
regard, combined block of atrial-specific K+ channels may be
favorable. Recently, another two families of K+-channels that are
dominantly expressed in the atria have been acknowledged: the
small-conductance Ca2+-activated K+ (SK) channels (ISK) (Qi
et al., 2014), and the two-pore K+ (K2P3.1) channel (ITASK−1)
(Schmidt et al., 2015), further to the well-known constitutively
active acetylcholine-activated K+ current (IK,ACh). Combined
block of these atrial-specific channels may exert greater and
safer antiarrhythmic effects in the atria, warranting future
investigations.
Synergistic Effects of Combined Na+- and
K+- Block
The present study reveals novel and significant synergistic
effects of combined block of Na+- and K+-currents (INa
and pure-IKur/multi-K
+-block) and demonstrates the additional
synergistic anti-arrhythmic effects derived from the multi-K+
channel block in cAF-remodeled atria.
In cAF-remodeled atria, combined Na+- and K+-block
significantly increased the fractional INa inhibition and APD
prolongation (Figures 3, 4) and promoted pronounced AP
alternans at 6Hz, with complex effects in human AF (Narayan
et al., 2011). In the simulations varying the blockade kinetics
of INa block, the combined block dramatically augmented the
attainable maximal AF-selectivity in consequence of enhanced
atrial-selectivity and rate-selectivity as compared to the pure
Na+-block (Figure 6).
In the 1D model of an atrial strand, combined Na+ and
K+-block produced synergistic reductions in Vmax and CV; the
threshold of BCL allowing a 1:1 conduction was increased as
compared to the control conditions (Figure 5). In simulated
re-entrant waves in 2D and 3D atria, the combined Bl·INa +
Comb·Bl·IX exhibited a greater efficacy in suppressing AF, with
a decreased lifespan of rotors as compared to that by either
individual block (Figures 7–9). Although the combined Bl·INa
+ Bl·IKur did not further reduce the lifespan of spiral waves
as compared to the Bl·INa alone, the combination did lead to
the extinction of one of the two rotors (Figures 7Aiv,Biv) and
deceleration of re-entrant activations (Figure 8B). Follow-up
simulations showed that consistent synergistic antiarrhythmic
effects could be obtained with reduced doses of Na+- and K+-
blockers.
The non-specific multi-channel blockade is increasingly
recognized as a strategy for pharmaceutical therapy of AF
both experimentally (Sicouri et al., 2010; Aguilar et al., 2015;
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Kirchhoff et al., 2015; Hartmann et al., 2016) and clinically
(Koskinas et al., 2014; Reiffel et al., 2015). In a previous study
(Aguilar et al., 2015), synergistic anti-arrhythmic effects were
demonstrated both in silico and experimentally in healthy canine
hearts. Additionally, the favorable synergistic antiarrhythmic
effects have also been reported in combined block of ISK and INa
in an experimental atrial-fibrillated guinea pig model (Kirchhoff
et al., 2015). Also, the recent HARMONY trial (Reiffel et al., 2015)
revealed synergistic AF-suppressing effects for combined use
of ranolazine and dronedarone. While revealing the synergistic
effects of combined Na+- and K+- block in cAF-remodeled
human atria, this study supports and adds insights into the on-
going efforts in developing multi-channel block as a strategy for
the treatment of AF.
Limitations and Future Work
In the absence of the required detailed experimental data, when
simulating effects of acacetin on Ito, IKs and IKr, the dose-
dependence block of acacetin was assumed to be identical in both
human atrial and ventricular cells. This assumption may warrant
further investigations. In addition, the parameters of atrial Ito
have been reported to be different from those of ventricular Ito
in human (Amos et al., 1996). Previous studies reported that
the IC50 of 4-AP block of atrial Ito was one-third of that of
ventricular Ito (Amos et al., 1996; Nattel et al., 2000). If a similar
atrial-vs.-ventricular difference in the IC50 of Ito and/or IKr/IKs
could exist for acacetin, the effects of acacetin on the ventricular
electrophysiology would be less significant than our simulations,
which might result in to a smaller change in ventricular INa and
APD for the combined block of Bl·INa and Comb·Bl·IX, and
thus enhance the computed atrial-selectivity and AF-selectivity
of the combined block. Given that applying acacetin in vivo
did not prolong QT intervals in isolated rabbit hearts and
anesthetised dogs (Li et al., 2008), any significant prolongation of
the ventricular APD and QT interval is unlikely (Figures 3B, 4C,
10). Therefore, our assumption of no atrial-ventricular difference
in the potency of acacetin on K+-currents may not affect our
conclusions concerning the atrial-selectivity of combined Na+-
and K+-block.
Additionally, in the absence of detailed experimental data
for state-dependent block of Ito, IKr, and IKs by acacetin, the
block of these channels was modeled using a single pore block
model. The IC50 values (Table 1) were determined by fitting the
concentration-response relation of the step current at 40mV in
previous experimental studies (Li et al., 2008; Wu et al., 2011).
A recent study suggests that the IC50 values may be dependent
on the voltage protocols applied, and this cannot be reflected by
single pore models. In future studies, the pore block model for
Ito, IKr, and IKs can be replaced by a state-dependent block model
when such experimental data become available. Also, the present
work did not attempt to model the effects of acacetin on IK,ACh,
although the study shows the current is potently blocked by the
compound. The 2D and 3D simulations of atrial tissue, while
validated, may not fully capture the complexity of fibrosis-tissue
interfaces which are seen in structurally remodeled atria and were
not simulated in these monodomain experiments.
Thirdly, our simulation results showed a moderate QT
prolongation of around 20ms following applying both INa
blocker and acacetin. While a QT prolongation of less than
5ms does not raise a regulatory concern (Committee for
Medicinal Products for Human Use, 2012), implications of
QT prolongations between 5 and 20ms remain inconclusive
(Committee forMedicinal Products for HumanUse, 2005). In the
present study, though the extent of QT prolongation of 20ms is
far less than the threshold of discontinuation criteria of 60ms as
indicated in Committee for Medicinal Products for Human Use
(2005), it would indeed raise a positive flag in thorough QT tests
and necessitate extended safety assessment and intensive patient
monitoring during late stages of trials (Committee for Medicinal
Products for HumanUse, 2012). On the other hand, the approach
we used in accounting for the effects of acacetin on ventricular
myocytes may result in upper bound of QT prolongation, since
the potency of acacetin was assumed to be identical in atria and
ventricles.
Fourthly, the threshold in BCL inducing AP alternans was
increased by K+-block (Figure 5, Figure S5). However, AP
alternans seen at slower pacing rates has been linked with
occurrence of AF (Narayan et al., 2002, 2011). Therefore, the
increased threshold in BCL developing AF by K+-block can
be potentially proarrhythmic. The safety of K+-block and its
proarrhythmic potential in the atria should be addressed in
future studies.
Fifthly, there are limitations in the approaches used in
simulating the INa blockers in single myocytes and tissue.
Similar to previous studies (Aguilar-Shardonofsky et al., 2012;
Aguilar et al., 2015), in our simulations, the drug action on INa
was modeled through a state-dependent block assuming drugs
binding to both activated and inactivated states of INa, and
the gating variables of INa were modeled using an Hodgkin-
Huxley scheme. The limitations in this approach outlined
in Aguilar-Shardonofsky et al. (2012) therefore apply in the
present study. The results of the use-dependent block may
be affected by the models used (Aguilar-Shardonofsky et al.,
2012). However, the previous study (Aguilar-Shardonofsky et al.,
2012) compared this modeling scheme with simulations using a
Markov model, showing qualitative agreement in major findings.
Therefore, the major conclusions drawn from this study may
not be affected by the selected modeling approach for INa
and drug interactions. Furthermore, in optimizing the AF-
selectivity of the INa and K
+-current blockers, the concentrations
of Na+ and K+ blockers were fixed at 60 uM. This may
potentially impose limitations in discomposing the role of the
binding parameters in the modulatory effects of the blockers
because of the very slow kinetics of the drug binding to its
targeted channel at this high concentration. It warrants further
studies by varying the concentration of blockers to simulate
the optimized effects of the AF-selectivity of INa blocker. In
tissue simulations, effects of drugs were modeled by increasing
their doses homogeneously, simultaneously and instantaneously.
The realistic actions of INa blockers in tissue, however, may
be different. Also, in tissue simulations a homogenous cell
model was used. As previous study (Feng et al., 1998b) showed
atria are electrically heterogeneous, future work is needed to
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assess how tissue heterogeneities affect the efficacy of atrial-
selective pharmaceutical interventions. Furthermore, the current
simulations did not take the cardiac autonomic regulation into
account in order to take into considerations of acacetin on IKACh.
Future studies on interactions of atrial-selective anti-arrhythmic
drug actions and autonomic systems may also render valuable
findings.
It is important to acknowledge that administration of class Ic
agents for Na+-block can cause cardiac arrhythmia and increased
mortality (Echt et al., 1991). Further investigations are therefore
warranted to assess the safety of the simulated Na+-block in the
heart, especially in the ventricles.
CONCLUSIONS
By using state-dependent drug block models and our
mathematical models of the human atria, the antiarrhythmic
effects of atrial selective Na+- and K+-blockers on the cAF-
remodeled atria were evaluated. The combined block of multiple
K+-currents as well as simultaneous block of Na+- and K+-
currents produced synergistic antiarrhythmic effects. Our results
suggest that developing multi-channel (multiple K+ currents
and/or combined Na+- and K+-current) block is a potentially
valuable strategy for the treatment of AF.
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